Skip to main content

Advertisement

SpringerLink
Log in

Leflunomide in dialysis patients with rheumatoid arthritis—a pharmacokinetic study

  • Brief Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Pharmacokinetic data of disease modifying antirheumatic drugs during hemodialysis are limited to sulfasalazine, methotrexate, and cyclosporine. Only respective anecdotal data have been reported on leflunomide. We repeatedly measured teriflunomide (A77-1726), the active metabolite of leflunomide, during standard hemodialysis sessions and calculated teriflunomide clearances in five patients with rheumatoid arthritis (RA) and end-stage renal disease. The calculated teriflunomide clearances during a standardized dialysis session of 3–4.5 h at a blood flow rate of 160–300 ml/min were between 0 and 4.3 ml/min, the mean clearances of the total dialysis ranged between 1.1 and 3.4 ml/min. Total amount of teriflunomide removed was 5.8–8.8 μg per dialysis session. Dialytic removal of the active metabolite of leflunomide, teriflunomide (A77-1726), is negligible. Leflunomide can be used for RA patients on chronic dialysis without any dosage modification.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Product Information Immunosporin (Cyclosporine), Novartis Pharma, last update 9/2011

  2. Product Information Azulfidine RA (Sulfasalazine), Pfizer, last update 5/2009

  3. Product Information Lantarel (MTX), Pfizer, last update 11/2010

  4. Product Information Arava (Leflunomide), Sanofi Aventis, last update 11/2011

  5. Ellman MH, Ginsberg D (1990) Low-dose methotrexate and severe neutropenia in patients undergoing renal dialysis. Arthritis Rheum 33:1060–1061

    Article  PubMed  CAS  Google Scholar 

  6. Boulanger H, Launay-Vacher V, Hierniaux P, Fau JB, Deray G (2001) Severe methotrexate intoxication in a haemodialysis patient treated for rheumatoid arthritis. Nephrol Dial Transplant 16:1087

    Article  PubMed  CAS  Google Scholar 

  7. Yang CP, Kuo MC, Guh JY, Chen HC (2006) Pancytopenia after low dose methotrexate therapy in a hemodialysis patient: case report and review of literature. Ren Fail 28:95–97

    Article  PubMed  CAS  Google Scholar 

  8. Teshima D, Hino B, Makino K, Yano T, Itoh Y, Joh Y, Iida M, Oishi R (2003) Sulphasalazine-induced leucopenia in a patient with renal dysfunction. J Clin Pharm Ther 28:239–242

    Article  PubMed  CAS  Google Scholar 

  9. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, Loew-Friedrich I, Oed C, Rosenburg R (1999) Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 23(353):259–266

    Article  Google Scholar 

  10. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, Fox R, Moreland L, Olsen N, Furst D, Caldwell J, Kaine J, Sharp J, Hurley F, Loew-Friedrich I (1999) Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 159:2542–2550

    Article  PubMed  CAS  Google Scholar 

  11. Rozman B (2002) Clinical pharmacokinetics of leflunomide. Clin Pharmacokinet 41:421–430

    Article  PubMed  CAS  Google Scholar 

  12. Li J, Yao HW, Jin Y et al (2002) Pharmacokinetics of leflunomide in Chinese healthy volunteers. Acta Pharmacol Sin 23:551–555

    PubMed  CAS  Google Scholar 

  13. Lucien J, Dias VC, Le Gatt DF, Yatscoff RW (1995) Blood distribution and single-dose pharmacokinetics of leflunomide. Ther Drug Monit 17:454–459

    Article  PubMed  CAS  Google Scholar 

  14. Keller F, Wilms H, Schultze G, Offerman G, Molzahn M (1983) Effect of plasma protein binding, volume of distribution and molecular weight on the fraction of drugs eliminated by hemodialysis. Clin Nephrol 19:201–205

    PubMed  CAS  Google Scholar 

  15. Bergner R, Dill K, Boerner D, Uppenkamp M (2002) Elimination of intravenously administered ibandronate in patients on hemodialysis: a monocenter open study. Nephrol Dial Transplant 17:1281–1285

    Article  PubMed  CAS  Google Scholar 

  16. Dias VC, Lucien J, Le Gatt DF, Yatscoff RW (1995) Measurement of the active leflunomide metabolite (A77 1726) by reverse-phase high-performance liquid chromatography. Ther Drug Monit 17:84–88

    Article  PubMed  CAS  Google Scholar 

  17. Beaman JM, Hackett LP, Luxton G, Illett KF (2002) Effect of hemodialysis on leflunomide plasma concentrations. Ann Pharmacother 36:75–77

    Article  PubMed  Google Scholar 

  18. Iwamoto M, Homma S, Asano Y, Minota S (2005) Administration of leflunomide to a patient with rheumatoid arthritis on haemodialysis. Scand J Rheumatol 34:410–411

    Article  PubMed  CAS  Google Scholar 

  19. Van Roon EN, Jansen TLTA, van de Laar MAFJ, Yska JP, Keuper R, Houtmann PM, Brouwers JRBJ (2005) Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 64:569–574

    Article  PubMed  CAS  Google Scholar 

  20. Akiyama Y, Fujimaki T, Sakurai Y (2003) Pharmacokinetics of salazosulfapyridine in a hemodialysis patient. Ryumachi 43:569–576

    PubMed  Google Scholar 

  21. Wall SM, Johansen MJ, Molony DA, Du Bose TD, Jaffe N, Madden T (1996) Effective clearance of methotrexate using high-flux hemodialysis membranes. Am J Kidney Dis 28:846–854

    Article  PubMed  CAS  Google Scholar 

  22. Diskin CJ, Stokes TJ, Dansby LM, Radcliff L, Carter TB (2006) Removal of methotrexate by peritoneal dialysis and hemodialysis in a single patient with end-stage renal disease. Am J Med Sci 332:156–158

    Article  PubMed  Google Scholar 

  23. Murashima M, Adamski J, Milone MC, Shaw L, Tsai DE, Bloom RD (2009) Methotrexate clearance by high-flux hemodialysis and peritoneal dialysis: a case report. Am J Kidney Dis 53:871–874

    Article  PubMed  CAS  Google Scholar 

  24. Venkataramanan R, Ptachcinski RJ, Burckart GJ, Yang SL, Starzl TE, Van Theil DH (1984) The clearance of cyclosporine by hemodialysis. J Clin Pharmacol 24:528–531

    PubMed  CAS  Google Scholar 

  25. Kullinger B, Wolfram J, Hamilton G, Horzemsky M, Kovarik J, Woloszczuk W, Steiner G (1990) Pharmacokinetics and metabolism of cyclosporine A in 19 hemodialysis patients. Transplant Proc 22:1702–1705

    PubMed  CAS  Google Scholar 

Download references

Disclosures

None.

Author information

Authors and Affiliations

  1. Medizinische Klinik A, Klinikum Ludwigshafen, Bremserstraße 79, 67063, Ludwigshafen, Germany

    Raoul Bergner, Lena Peters, Verena Schmitt & Christian Löffler

Authors
  1. Raoul Bergner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lena Peters
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Verena Schmitt
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Christian Löffler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Raoul Bergner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bergner, R., Peters, L., Schmitt, V. et al. Leflunomide in dialysis patients with rheumatoid arthritis—a pharmacokinetic study. Clin Rheumatol 32, 267–270 (2013). https://doi.org/10.1007/s10067-012-2122-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-012-2122-1

Keywords

Search

Navigation